The biotech sector in the Greater Munich area continues to demonstrate significant growth in revenue and staff numbers despite ever-increasing international competition. This continues Munich’s status as one of the pre-eminent locations for this future-oriented industry. This was confirmed by the latest study carried out by the City of Munich, the IHK and BioM based on a survey and questionaire of different businesses and experts.
In 2013, 23,000 people were working here in a total of 377 biotechnology and pharmaceutical companies, generating a turnover of around 8.5 billion euros (not including companies from the medical engineering sector). This is in addition to around 10,000 employees in public and private research facilities and universities.
According to criteria set out by the OECD, around 15 % of German biotechnology firms have their headquarters in the Greater Munich area, with 30 % of the nation’s biotechnological development of drugs taking place here.
The local nucleus of companies researching, developing and manufacturing therapeutic and diagnostic agents comprises the area around the IZB (Innovation and Start-Up Centre for Biotechnology) in Martinsried,